Field & Main Bank Acquires 45 Shares of Amgen Inc. (NASDAQ:AMGN)

Field & Main Bank lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,393 shares of the medical research company’s stock after purchasing an additional 45 shares during the period. Field & Main Bank’s holdings in Amgen were worth $2,129,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in AMGN. Vanguard Group Inc. increased its holdings in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after purchasing an additional 165,636 shares during the period. Northern Trust Corp lifted its stake in Amgen by 3.8% in the third quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock worth $1,875,306,000 after acquiring an additional 255,463 shares during the period. Bank of New York Mellon Corp grew its holdings in Amgen by 1.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 5,437,182 shares of the medical research company’s stock worth $1,461,297,000 after acquiring an additional 61,528 shares in the last quarter. Royal Bank of Canada increased its position in Amgen by 11.4% during the 3rd quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock valued at $1,365,213,000 after purchasing an additional 518,689 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Amgen by 15.9% in the 3rd quarter. Invesco Ltd. now owns 3,356,359 shares of the medical research company’s stock valued at $902,055,000 after purchasing an additional 459,340 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of several research reports. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Truist Financial restated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. Oppenheimer reiterated an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research note on Thursday, February 1st. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, The Goldman Sachs Group lifted their price objective on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $297.40.

Amgen Stock Performance

NASDAQ:AMGN traded up $6.40 during midday trading on Monday, hitting $276.38. The company’s stock had a trading volume of 2,678,923 shares, compared to its average volume of 2,820,901. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The firm’s 50 day moving average is $274.96 and its 200-day moving average is $281.45. The firm has a market cap of $148.24 billion, a P/E ratio of 22.13, a P/E/G ratio of 2.61 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the firm posted $4.09 earnings per share. Equities analysts anticipate that Amgen Inc. will post 19.43 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.26%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.